La. Maier et al., High beryllium-stimulated TNF-alpha is associated with the-308 TNF-alpha promoter polymorphism and with clinical severity in chronic beryllium disease, AM J R CRIT, 164(7), 2001, pp. 1192-1199
Beryllium (Be)-antigen stimulates tumor necrosis factor-alpha (TNF-alpha) f
rom bronchoalveolar lavage (BAL) cells in chronic beryllium disease (CBD).
This study tested the hypothesis that high concentrations of Be-stimulated
TNF-alpha are related to polymorphisms in the TNF-alpha promoter and clinic
al markers of disease severity in CBD. Demographic and clinical information
was obtained from patients with CBD (n = 20). TNF-alpha concentrations wer
e measured in BAL cell culture supernatant by ELISA. A prior), we categoriz
ed CBD subjects as either high or low TNF-alpha producers using a cutoff of
1,500 pg/ml. The TNF-alpha promoter sequence, +64 to -1045, was determined
by direct sequencing. Human leukocyte-associated antigen (HLA)-DPB1 and -D
RB1 genotyping was determined by polymerase chain reaction (PCR). High Be-s
timulated TNF-alpha was associated with TNF2 alleles, Hispanic ethnicity, p
resence of HLA-DPB1 Glu69, and absence of HLA-DR4. Be-stimulated TNF-alpha
concentrations correlated with markers of disease severity, including chest
radiograph, beryllium lymphocyte proliferation, and spirometry. We found n
o novel TNF-alpha promoter polymorphisms. These data suggest that the TNF2
A allele at -308 in the TNF-alpha promoter region is a functional polymorph
ism, associated with a high level of Be-antigen-stimulated TNF-alpha and th
at these high TNF-alpha levels indicate disease severity in CBD.